Literature DB >> 27207798

The role of whole brain radiation in primary CNS lymphoma.

Benjamin Kasenda1, Jay Loeffler2, Gerald Illerhaus1, Andrés J M Ferreri3, James Rubenstein4, Tracy T Batchelor5.   

Abstract

Entities:  

Mesh：

Year:  2016        PMID： 27207798      PMCID： PMC4968379          DOI： 10.1182/blood-2016-01-650101

Source DB:  PubMed          Journal:  Blood        ISSN： 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  36 in total

1.  R-MPV followed by high-dose chemotherapy with TBC and autologous stem-cell transplant for newly diagnosed primary CNS lymphoma.

Authors:  Antonio Omuro; Denise D Correa; Lisa M DeAngelis; Craig H Moskowitz; Matthew J Matasar; Thomas J Kaley; Igor T Gavrilovic; Craig Nolan; Elena Pentsova; Christian C Grommes; Katherine S Panageas; Raymond E Baser; Geraldine Faivre; Lauren E Abrey; Craig S Sauter
Journal:  Blood       Date:  2015-01-07       Impact factor: 22.113

Review 2.  Primary central nervous system lymphoma.

Authors:  Elizabeth R Gerstner; Tracy T Batchelor
Journal:  Arch Neurol       Date:  2010-03

3.  Results of whole-brain radiation as salvage of methotrexate failure for immunocompetent patients with primary CNS lymphoma.

Authors:  Paul L Nguyen; Arnab Chakravarti; Dianne M Finkelstein; Fred H Hochberg; Tracy T Batchelor; Jay S Loeffler
Journal:  J Clin Oncol       Date:  2005-03-01       Impact factor: 44.544

Review 4.  First-line treatment and outcome of elderly patients with primary central nervous system lymphoma (PCNSL)--a systematic review and individual patient data meta-analysis.

Authors:  B Kasenda; A J M Ferreri; E Marturano; D Forst; J Bromberg; H Ghesquieres; C Ferlay; J Y Blay; K Hoang-Xuan; E J Pulczynski; A Fosså; Y Okoshi; S Chiba; K Fritsch; A Omuro; B P O'Neill; O Bairey; S Schandelmaier; V Gloy; N Bhatnagar; S Haug; S Rahner; T T Batchelor; G Illerhaus; M Briel
Journal:  Ann Oncol       Date:  2015-02-20       Impact factor: 32.976

5.  Long-term follow-up of high-dose methotrexate-based therapy with and without whole brain irradiation for newly diagnosed primary CNS lymphoma.

Authors:  Igor T Gavrilovic; Adília Hormigo; Joachim Yahalom; Lisa M DeAngelis; Lauren E Abrey
Journal:  J Clin Oncol       Date:  2006-10-01       Impact factor: 44.544

Review 6.  The role of additional radiotherapy for primary central nervous system lymphoma.

Authors:  Jonas Zacher; Benjamin Kasenda; Andreas Engert; Nicole Skoetz
Journal:  Cochrane Database Syst Rev       Date:  2014-06-16

7.  Increasing incidence and continued dismal outcome of primary central nervous system lymphoma in Norway 1989-2003 : time trends in a 15-year national survey.

Authors:  Ingfrid S Haldorsen; Bård K Krossnes; Jan H Aarseth; David Scheie; Tom B Johannesen; Olav Mella; Ansgar Espeland
Journal:  Cancer       Date:  2007-10-15       Impact factor: 6.860

8.  Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202).

Authors:  James L Rubenstein; Eric D Hsi; Jeffrey L Johnson; Sin-Ho Jung; Megan O Nakashima; Barbara Grant; Bruce D Cheson; Lawrence D Kaplan
Journal:  J Clin Oncol       Date:  2013-04-08       Impact factor: 44.544

9.  Preirradiation chemotherapy with cyclophosphamide, doxorubicin, vincristine, and dexamethasone for primary CNS lymphomas: initial report of radiation therapy oncology group protocol 88-06.

Authors:  C Schultz; C Scott; W Sherman; B Donahue; J Fields; K Murray; B Fisher; R Abrams; J Meis-Kindblom
Journal:  J Clin Oncol       Date:  1996-02       Impact factor: 44.544

10.  Salvage whole brain radiotherapy for recurrent or refractory primary CNS lymphoma.

Authors:  Andreas F Hottinger; Lisa M DeAngelis; Joachim Yahalom; Lauren E Abrey
Journal:  Neurology       Date:  2007-09-11       Impact factor: 9.910
View more
  17 in total

1.  Therapy and outcomes of primary central nervous system lymphoma in the United States: analysis of the National Cancer Database.

Authors:  Jaleh Fallah; Lindor Qunaj; Adam J Olszewski
Journal:  Blood Adv       Date:  2016-11-30

Review 2.  Therapy of primary CNS lymphoma: role of intensity, radiation, and novel agents.

Authors:  Andrés José María Ferreri
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2017-12-08

3.  Phase 1 investigation of lenalidomide/rituximab plus outcomes of lenalidomide maintenance in relapsed CNS lymphoma.

Authors:  James L Rubenstein; Huimin Geng; Eleanor J Fraser; Paul Formaker; Lingjing Chen; Jigyasa Sharma; Phoebe Killea; Kaylee Choi; Jenny Ventura; John Kurhanewicz; Clifford Lowell; Jimmy Hwang; Patrick Treseler; Penny K Sneed; Jing Li; Xiaomin Wang; Nianhang Chen; Jon Gangoiti; Pamela N Munster; Bertil Damato
Journal:  Blood Adv       Date:  2018-07-10

4.  PD-1 blockade with nivolumab in relapsed/refractory primary central nervous system and testicular lymphoma.

Authors:  Lakshmi Nayak; Fabio M Iwamoto; Ann LaCasce; Srinivasan Mukundan; Margaretha G M Roemer; Bjoern Chapuy; Philippe Armand; Scott J Rodig; Margaret A Shipp
Journal:  Blood       Date:  2017-03-29       Impact factor: 22.113

5.  Selective salvage radiotherapy could provide favorable outcomes in patients with refractory or relapsed primary central nervous system lymphoma.

Authors:  Nalee Kim; Do Hoon Lim; Sang Eun Yoon; Seok Jin Kim; Won Seog Kim
Journal:  J Neurooncol       Date:  2021-12-01       Impact factor: 4.130

6.  Primary central nervous system lymphoma: a real-world comparison of therapy access and outcomes by hospital setting.

Authors:  Akshat M Patel; Omer Ali; Radhika Kainthla; Syed M Rizvi; Farrukh T Awan; Toral Patel; Edward Pan; Elizabeth Maher; Neil B Desai; Robert Timmerman; Kiran A Kumar; Praveen Ramakrishnan Geethakumari
Journal:  Neurooncol Pract       Date:  2022-01-12

7.  The Diagnosis and Treatment of Primary CNS Lymphoma.

Authors:  Louisa von Baumgarten; Gerald Illerhaus; Agnieszka Korfel; Uwe Schlegel; Martina Deckert; Martin Dreyling
Journal:  Dtsch Arztebl Int       Date:  2018-06-22       Impact factor: 5.594

8.  Outcomes Associated With Thiotepa-Based Conditioning in Patients With Primary Central Nervous System Lymphoma After Autologous Hematopoietic Cell Transplant.

Authors:  Michael Scordo; Trent P Wang; Kwang W Ahn; Yue Chen; Sairah Ahmed; Farrukh T Awan; Amer Beitinjaneh; Andy Chen; Victor A Chow; Bhagirathbhai Dholaria; Narendranath Epperla; Umar Farooq; Nilanjan Ghosh; Natalie Grover; Nada Hamad; Gerhard C Hildebrandt; Leona Holmberg; Sanghee Hong; David J Inwards; Antonio Jimenez-Jimenez; Reem Karmali; Vaishalee P Kenkre; Farhad Khimani; Evgeny Klyuchnikov; Maxwell M Krem; Pashna N Munshi; Yago Nieto; Tim Prestidge; Praveen Ramakrishnan Geethakumari; Andrew R Rezvani; Peter A Riedell; Sachiko Seo; Nirav N Shah; Melhem Solh; Jean A Yared; Mohamed A Kharfan-Dabaja; Alex Herrera; Mehdi Hamadani; Craig S Sauter
Journal:  JAMA Oncol       Date:  2021-07-01       Impact factor: 31.777

9.  Lenalidomide and Temozolomide Combination in a Very Elderly Patient with CNS Relapse of Diffuse Large B-Cell Lymphoma.

Authors:  Emanuele Cencini; Alberto Fabbri; Umberto Arrigucci; Alfonso Cerase; Monica Bocchia
Journal:  Mediterr J Hematol Infect Dis       Date:  2017-06-16       Impact factor: 2.576

Review 10.  Is There an Indication for First Line Radiotherapy in Primary CNS Lymphoma?

Authors:  Clemens Seidel; Christine Viehweger; Rolf-Dieter Kortmann
Journal:  Cancers (Basel)       Date:  2021-05-25       Impact factor: 6.639
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.